AI Engines For more Details: Perplexity Kagi Labs You
Allergy Relief: Pheniramine maleate is primarily used to relieve symptoms associated with allergic conditions, such as sneezing, itching, watery eyes, and runny nose. It works by blocking the effects of histamine, a substance produced by the body during allergic reactions.
Common Cold Relief: Pheniramine maleate is also used to alleviate symptoms of the common cold, including nasal congestion, cough, and sore throat. By reducing inflammation in the nasal passages and suppressing cough reflexes, it helps improve breathing and overall comfort.
Sedation: Pheniramine maleate has sedative effects, which can help alleviate symptoms such as insomnia or difficulty falling asleep caused by allergic reactions or cold symptoms. However, sedation can also cause drowsiness and impair cognitive function, so caution should be exercised when operating machinery or driving.
Anti-itching: Due to its antihistamine properties, pheniramine maleate can effectively reduce itching associated with allergic skin conditions like urticaria (hives) and eczema. It blocks histamine receptors in the skin, thereby reducing itching sensations.
Antiemetic: In some cases, pheniramine maleate may be used as an antiemetic (anti-nausea medication) to alleviate nausea and vomiting associated with motion sickness or certain medical conditions. Its mechanism of action in this regard is not fully understood but may involve central nervous system effects.
Dry Mouth: One common side effect of pheniramine maleate is dry mouth. This occurs due to the medication's anticholinergic properties, which can reduce saliva production. Patients should stay hydrated and consider using sugar-free lozenges or gum to alleviate dry mouth symptoms.
Urinary Retention: Pheniramine maleate can cause urinary retention, particularly in men with prostate enlargement (benign prostatic hyperplasia). This side effect may lead to difficulty urinating or incomplete emptying of the bladder.
Blurred Vision: Some individuals may experience blurred vision or difficulty focusing while taking pheniramine maleate. This effect is usually temporary and resolves once the medication is discontinued.
Constipation: Pheniramine maleate's anticholinergic effects can slow down bowel motility and lead to constipation in some individuals. Maintaining adequate hydration and consuming fiber-rich foods can help alleviate this side effect.
Increased Heart Rate: In rare cases, pheniramine maleate may cause tachycardia (rapid heart rate), especially at higher doses or in susceptible individuals. Patients with pre-existing cardiovascular conditions should use pheniramine maleate cautiously and under medical supervision.
Interactions: Pheniramine maleate may interact with other medications, including central nervous system depressants, anticholinergic drugs, and monoamine oxidase inhibitors (MAOIs). Patients should inform their healthcare provider about all medications they are taking to avoid potential drug interactions.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Fusobacterium | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Fusobacterium nucleatum | species | Decreases |
| 1 | 0 | Parabacteroides merdae | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| ADHD | 1 | 0.3 | 2.33 |
| Age-Related Macular Degeneration and Glaucoma | 0.4 | -0.4 | |
| Allergic Rhinitis (Hay Fever) | 0.7 | 0.3 | 1.33 |
| Allergies | 0.7 | 0.3 | 1.33 |
| Allergy to milk products | 0.3 | 0.4 | -0.33 |
| Alzheimer's disease | 1.2 | 0.6 | 1 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.3 | 0.3 | |
| Ankylosing spondylitis | 0.3 | 0.3 | 0 |
| Anorexia Nervosa | 0.7 | 0.3 | 1.33 |
| Antiphospholipid syndrome (APS) | 0.3 | 0.3 | 0 |
| Asthma | 0.9 | 0.3 | 2 |
| Atherosclerosis | 0.3 | 0.3 | |
| Atrial fibrillation | 1 | 0.7 | 0.43 |
| Autism | 1.3 | 1.6 | -0.23 |
| Autoimmune Disease | 0.3 | 0.3 | |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| Biofilm | 0.5 | 0.5 | |
| Bipolar Disorder | 0.7 | 0.3 | 1.33 |
| Brain Trauma | 0.3 | 0.3 | |
| Breast Cancer | 0.2 | 0.2 | |
| Cancer (General) | 0.3 | 0.3 | |
| Carcinoma | 1.5 | 0.4 | 2.75 |
| Celiac Disease | 0.3 | 0.7 | -1.33 |
| Cerebral Palsy | 0.3 | 0.3 | |
| Chronic Fatigue Syndrome | 0.6 | 1.1 | -0.83 |
| Chronic Kidney Disease | 0.4 | 0.6 | -0.5 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.2 | 0.9 | 0.33 |
| Chronic Urticaria (Hives) | 0.3 | 0.3 | |
| Coagulation / Micro clot triggering bacteria | 0.7 | 0.3 | 1.33 |
| Cognitive Function | 0.7 | 0.3 | 1.33 |
| Colorectal Cancer | 1.5 | 1.5 | |
| Coronary artery disease | 0.3 | 0.3 | 0 |
| COVID-19 | 1.2 | 0.9 | 0.33 |
| Crohn's Disease | 1.8 | 1 | 0.8 |
| deep vein thrombosis | 0.5 | 0.3 | 0.67 |
| Denture Wearers Oral Shifts | 0.8 | 0.8 | |
| Depression | 1.6 | 1.5 | 0.07 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 0.6 | 0.6 | 0 |
| Endometriosis | 1 | 0.3 | 2.33 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 0.6 | 0.6 | 0 |
| erectile dysfunction | 0.3 | 0.3 | |
| Fibromyalgia | 0.6 | 0.3 | 1 |
| Functional constipation / chronic idiopathic constipation | 1 | 0.7 | 0.43 |
| gallstone disease (gsd) | 0.4 | 0.3 | 0.33 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.5 | 0.3 | 0.67 |
| Generalized anxiety disorder | 0.9 | 0.6 | 0.5 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.3 | 0.3 | 0 |
| Graves' disease | 0.4 | 0.3 | 0.33 |
| Gulf War Syndrome | 0.6 | 0.6 | |
| Halitosis | 0.8 | 0.3 | 1.67 |
| Hashimoto's thyroiditis | 0.3 | 0.3 | 0 |
| Heart Failure | 1.2 | 1.2 | |
| hemorrhagic stroke | 0.7 | 0.7 | |
| Hidradenitis Suppurativa | 0.9 | 0.9 | |
| hyperglycemia | 0.3 | 0.4 | -0.33 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 0.9 | 0.9 | 0 |
| Hypothyroidism | 0.3 | -0.3 | |
| Hypoxia | 0.4 | 0.4 | |
| IgA nephropathy (IgAN) | 1 | 1 | |
| Inflammatory Bowel Disease | 1.5 | 0.9 | 0.67 |
| Insomnia | 0.9 | 0.3 | 2 |
| Intelligence | 0.3 | 0.3 | |
| Intracranial aneurysms | 0.7 | 0.3 | 1.33 |
| Irritable Bowel Syndrome | 0.5 | 1 | -1 |
| ischemic stroke | 0.7 | 0.7 | |
| Liver Cirrhosis | 1.9 | 1.2 | 0.58 |
| Long COVID | 1.3 | 1.3 | 0 |
| Low bone mineral density | 0.3 | -0.3 | |
| Lung Cancer | 0.3 | 0.3 | |
| Mast Cell Issues / mastitis | 0.5 | 0.3 | 0.67 |
| ME/CFS with IBS | 0.3 | 0.3 | 0 |
| ME/CFS without IBS | 0.3 | 0.3 | |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.3 | |
| Metabolic Syndrome | 1.7 | 1.6 | 0.06 |
| Mood Disorders | 1.6 | 1.5 | 0.07 |
| multiple chemical sensitivity [MCS] | 0.6 | 0.6 | |
| Multiple Sclerosis | 1.6 | 1 | 0.6 |
| myasthenia gravis | 0.3 | 0.3 | |
| neuropathic pain | 0.4 | -0.4 | |
| Neuropathy (all types) | 0.3 | 0.4 | -0.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.6 | 0.3 | 1 |
| Obesity | 1.6 | 1.8 | -0.13 |
| obsessive-compulsive disorder | 0.7 | 0.6 | 0.17 |
| Osteoarthritis | 0.3 | 0.3 | 0 |
| Osteoporosis | 0.3 | -0.3 | |
| pancreatic cancer | 0.5 | 0.3 | 0.67 |
| Parkinson's Disease | 1.6 | 0.9 | 0.78 |
| Polycystic ovary syndrome | 1.4 | 0.6 | 1.33 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0.3 | 0.6 | -1 |
| Primary sclerosing cholangitis | 1 | 0.7 | 0.43 |
| Psoriasis | 0.3 | 0.7 | -1.33 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.5 | 0.6 | 1.5 |
| Schizophrenia | 1.6 | 0.7 | 1.29 |
| scoliosis | 0.3 | 0.3 | 0 |
| Sjögren syndrome | 0.7 | 0.4 | 0.75 |
| Sleep Apnea | 0.6 | 0.3 | 1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.9 | 0.9 | |
| Stress / posttraumatic stress disorder | 0.7 | 0.7 | 0 |
| Systemic Lupus Erythematosus | 1.6 | 1.6 | |
| Tic Disorder | 0.3 | 0.3 | |
| Tourette syndrome | 0.3 | 0.3 | |
| Type 1 Diabetes | 0.9 | 0.3 | 2 |
| Type 2 Diabetes | 1.6 | 1.3 | 0.23 |
| Ulcerative colitis | 0.9 | 1 | -0.11 |
| Unhealthy Ageing | 1.4 | 0.7 | 1 |
| Vitiligo | 0.7 | 0.7 | 0 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
